Last updated: April 25, 2026
Who Supplies Uroxatral (Alfuzosin) in the US?
Uroxatral is the brand name for alfuzosin extended-release (ER) tablets. The primary commercial supply for the US market typically sits with the brand product holder and its authorized commercial manufacturers (contract manufacturing organizations) and the licensed distributors that support wholesalers and pharmacy channels.
Because “supplier” can mean different roles (brand owner, manufacturing site, marketing authorization holder, or wholesale distributor), the actionable way to map supply is through (1) who holds the US brand label and (2) which firms manufacture/pack the marketed product. Without those specific label-level identifiers for the exact product strength and package, a complete supplier list cannot be produced accurately.
What Is the Correct Way to Identify Uroxatral Suppliers?
What qualifies as a “supplier”?
For a pharma supply map, the credible supplier set is limited to firms that appear on the commercial chain-of-custody documentation for Uroxatral, including:
- Market authorization and label responsibilities (brand holder / labeler)
- Manufacturing and packaging plants listed on the finished dosage form label
- Distributors/wholesalers tied to the NDC supply chain records
A supplier list that does not anchor to the NDC-specific labeler/manufacturer/packer is not decision-grade for R&D sourcing or investment diligence.
Uroxatral Supply Mapping (NDC-Dependent)
Uroxatral is marketed in multiple strengths and package configurations, each tied to distinct NDC records. A correct supplier list therefore must be NDC-specific.
What is missing to produce a complete, accurate supplier list?
A complete supplier list requires the following from the official US product labeling and NDC data for the specific Uroxatral presentation:
| Data element required |
Why it matters |
Must come from |
| NDC (exact) |
Identifies the exact marketed presentation |
FDA NDC directory / label |
| Labeler (US) |
Defines the commercial “who” on the bottle label |
Label/NDC record |
| Manufacturer/packer (US) |
Defines the manufacturing supplier |
Label/NDC record |
| Distributor / wholesaler identifiers |
Defines channel suppliers |
NDC supply/distributor data |
Absent these anchor fields, any named “suppliers” would risk being incomplete or misattributed.
Key Takeaways
- Uroxatral supply is NDC-specific. A supplier list must be tied to the exact marketed presentation.
- Decision-grade “suppliers” are label-anchored (labeler, manufacturer/packer, and channel distributor) rather than generic or historical statements.
- Without NDC-specific label/manufacturer/packer identifiers, a complete supplier list cannot be produced accurately.
FAQs
1) Who is the labeler for Uroxatral in the US?
It is the entity listed on the specific Uroxatral NDC’s bottle/label and corresponding FDA NDC record.
2) Are Uroxatral suppliers different by tablet strength (e.g., 10 mg vs. 20 mg)?
Yes. Different strengths and package configurations typically map to different NDCs, which can map to different manufacturing/packing records.
3) Does “supplier” mean the contract manufacturer or the brand owner?
In supply-chain terms, suppliers can include both, but the most defensible supplier list distinguishes labeler vs. manufacturer/packer vs. distributors.
4) Can I list Uroxatral suppliers without using NDC-level data?
No. NDC-level labeling and manufacturing/packing records are the basis for an accurate supplier mapping.
5) Where do authoritative supplier identifiers come from for US products?
From the FDA NDC directory/labeling data and the finished dosage form labeling that ties NDC to labeler and manufacturing/packing sites.
References
- FDA National Drug Code Directory. (n.d.). Uroxatral (alfuzosin). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/ndc/
- Uroxatral (alfuzosin) Prescribing Information and labeling (as listed for US NDC presentations). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
